nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—kidney cancer—Hydrocortisone—psoriasis	0.1	0.174	CpDpCtD
Celecoxib—colon cancer—Dexamethasone—psoriasis	0.0845	0.146	CpDpCtD
Celecoxib—colon cancer—Betamethasone—psoriasis	0.0845	0.146	CpDpCtD
Celecoxib—prostate cancer—Hydrocortisone—psoriasis	0.0724	0.125	CpDpCtD
Celecoxib—kidney cancer—Betamethasone—psoriasis	0.0611	0.106	CpDpCtD
Celecoxib—kidney cancer—Dexamethasone—psoriasis	0.0611	0.106	CpDpCtD
Celecoxib—prostate cancer—Betamethasone—psoriasis	0.0442	0.0766	CpDpCtD
Celecoxib—prostate cancer—Dexamethasone—psoriasis	0.0442	0.0766	CpDpCtD
Celecoxib—ALB—Acitretin—psoriasis	0.0294	0.131	CbGbCtD
Celecoxib—osteoarthritis—Prednisone—psoriasis	0.0249	0.0431	CpDpCtD
Celecoxib—PTGS2—Triamcinolone—psoriasis	0.0219	0.0976	CbGbCtD
Celecoxib—PTGS2—Betamethasone—psoriasis	0.0187	0.0837	CbGbCtD
Celecoxib—ABCC4—Methotrexate—psoriasis	0.0149	0.0666	CbGbCtD
Celecoxib—ALB—Mycophenolate mofetil—psoriasis	0.0138	0.0615	CbGbCtD
Celecoxib—CYP2D6—Hydroxyurea—psoriasis	0.0129	0.0577	CbGbCtD
Celecoxib—ALB—Prednisone—psoriasis	0.011	0.0492	CbGbCtD
Celecoxib—PTGS2—Dexamethasone—psoriasis	0.0109	0.0487	CbGbCtD
Celecoxib—CYP3A4—Calcitriol—psoriasis	0.00967	0.0432	CbGbCtD
Celecoxib—CYP2C9—Cholecalciferol—psoriasis	0.00857	0.0383	CbGbCtD
Celecoxib—CYP2D6—Cholecalciferol—psoriasis	0.00783	0.035	CbGbCtD
Celecoxib—CYP3A4—Methoxsalen—psoriasis	0.00752	0.0336	CbGbCtD
Celecoxib—CYP2C9—Cyclosporine—psoriasis	0.00563	0.0251	CbGbCtD
Celecoxib—ALB—Methotrexate—psoriasis	0.00553	0.0247	CbGbCtD
Celecoxib—CYP2D6—Cyclosporine—psoriasis	0.00515	0.023	CbGbCtD
Celecoxib—CYP3A4—Cholecalciferol—psoriasis	0.00498	0.0222	CbGbCtD
Celecoxib—CYP3A4—Triamcinolone—psoriasis	0.00432	0.0193	CbGbCtD
Celecoxib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00432	0.0193	CbGbCtD
Celecoxib—CYP2C9—Dexamethasone—psoriasis	0.00371	0.0166	CbGbCtD
Celecoxib—CYP3A4—Betamethasone—psoriasis	0.00371	0.0165	CbGbCtD
Celecoxib—CYP3A4—Prednisolone—psoriasis	0.00366	0.0163	CbGbCtD
Celecoxib—CYP3A4—Hydrocortisone—psoriasis	0.00347	0.0155	CbGbCtD
Celecoxib—CYP3A4—Prednisone—psoriasis	0.00345	0.0154	CbGbCtD
Celecoxib—CYP2D6—Dexamethasone—psoriasis	0.00339	0.0151	CbGbCtD
Celecoxib—CYP3A4—Cyclosporine—psoriasis	0.00327	0.0146	CbGbCtD
Celecoxib—CYP3A4—Dexamethasone—psoriasis	0.00216	0.00963	CbGbCtD
Celecoxib—ORM1—vertebral column—psoriasis	0.00102	0.229	CbGeAlD
Celecoxib—PTGS2—skeletal joint—psoriasis	0.000615	0.137	CbGeAlD
Celecoxib—PTGS2—synovial membrane of synovial joint—psoriasis	0.000467	0.104	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000369	0.157	CbGdCrCtD
Celecoxib—MAPK14—skin of body—psoriasis	0.000323	0.0722	CbGeAlD
Celecoxib—PTGS2—skin epidermis—psoriasis	0.0003	0.067	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000295	0.126	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000287	0.122	CbGdCrCtD
Celecoxib—CA9—tendon—psoriasis	0.000252	0.0563	CbGeAlD
Celecoxib—MAPK14—tendon—psoriasis	0.000246	0.0549	CbGeAlD
Celecoxib—CA14—tendon—psoriasis	0.000239	0.0534	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000222	0.0949	CbGdCrCtD
Celecoxib—PTGS2—endothelium—psoriasis	0.000217	0.0486	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000178	0.076	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000178	0.076	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000173	0.0738	CbGdCrCtD
Celecoxib—CA5B—tendon—psoriasis	0.000167	0.0374	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000135	0.0574	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000135	0.0574	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000131	0.0561	CbGdCrCtD
Celecoxib—CA2—skin of body—psoriasis	0.000126	0.0281	CbGeAlD
Celecoxib—ABCC4—tendon—psoriasis	0.000126	0.0281	CbGeAlD
Celecoxib—CA4—tendon—psoriasis	0.000115	0.0258	CbGeAlD
Celecoxib—CA2—tendon—psoriasis	9.57e-05	0.0214	CbGeAlD
Celecoxib—PTGS2—skin of body—psoriasis	9.28e-05	0.0207	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	8.12e-05	0.0346	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	8.12e-05	0.0346	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	7.93e-05	0.0338	CbGdCrCtD
Celecoxib—PTGS2—tendon—psoriasis	7.06e-05	0.0158	CbGeAlD
Celecoxib—Mental disorder—Prednisone—psoriasis	3.19e-05	0.000234	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.17e-05	0.000233	CcSEcCtD
Celecoxib—Hyperhidrosis—Triamcinolone—psoriasis	3.16e-05	0.000233	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—psoriasis	3.16e-05	0.000232	CcSEcCtD
Celecoxib—Feeling abnormal—Mycophenolate mofetil—psoriasis	3.14e-05	0.000231	CcSEcCtD
Celecoxib—Insomnia—Hydrocortisone—psoriasis	3.14e-05	0.000231	CcSEcCtD
Celecoxib—Hypertension—Betamethasone—psoriasis	3.14e-05	0.000231	CcSEcCtD
Celecoxib—Hypertension—Dexamethasone—psoriasis	3.14e-05	0.000231	CcSEcCtD
Celecoxib—Paraesthesia—Hydrocortisone—psoriasis	3.12e-05	0.000229	CcSEcCtD
Celecoxib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.12e-05	0.000229	CcSEcCtD
Celecoxib—Urticaria—Cyclosporine—psoriasis	3.11e-05	0.000228	CcSEcCtD
Celecoxib—Myalgia—Betamethasone—psoriasis	3.1e-05	0.000228	CcSEcCtD
Celecoxib—Myalgia—Dexamethasone—psoriasis	3.1e-05	0.000228	CcSEcCtD
Celecoxib—Abdominal pain—Cyclosporine—psoriasis	3.09e-05	0.000227	CcSEcCtD
Celecoxib—Body temperature increased—Cyclosporine—psoriasis	3.09e-05	0.000227	CcSEcCtD
Celecoxib—Anxiety—Betamethasone—psoriasis	3.09e-05	0.000227	CcSEcCtD
Celecoxib—Anxiety—Dexamethasone—psoriasis	3.09e-05	0.000227	CcSEcCtD
Celecoxib—Vomiting—Mycophenolic acid—psoriasis	3.07e-05	0.000226	CcSEcCtD
Celecoxib—Dyspepsia—Hydrocortisone—psoriasis	3.06e-05	0.000225	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—psoriasis	3.06e-05	0.000225	CcSEcCtD
Celecoxib—Rash—Mycophenolic acid—psoriasis	3.05e-05	0.000224	CcSEcCtD
Celecoxib—Dermatitis—Mycophenolic acid—psoriasis	3.05e-05	0.000224	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—psoriasis	3.04e-05	0.000224	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—psoriasis	3.04e-05	0.000224	CcSEcCtD
Celecoxib—Urticaria—Mycophenolate mofetil—psoriasis	3.03e-05	0.000223	CcSEcCtD
Celecoxib—Headache—Mycophenolic acid—psoriasis	3.03e-05	0.000223	CcSEcCtD
Celecoxib—Decreased appetite—Hydrocortisone—psoriasis	3.02e-05	0.000222	CcSEcCtD
Celecoxib—Pharyngitis—Methotrexate—psoriasis	3.02e-05	0.000222	CcSEcCtD
Celecoxib—Abdominal pain—Mycophenolate mofetil—psoriasis	3.02e-05	0.000222	CcSEcCtD
Celecoxib—Body temperature increased—Mycophenolate mofetil—psoriasis	3.02e-05	0.000222	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—psoriasis	3e-05	0.000221	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Hydrocortisone—psoriasis	3e-05	0.000221	CcSEcCtD
Celecoxib—Fatigue—Hydrocortisone—psoriasis	3e-05	0.00022	CcSEcCtD
Celecoxib—Vision blurred—Prednisone—psoriasis	2.99e-05	0.00022	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—psoriasis	2.98e-05	0.000219	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.98e-05	0.000219	CcSEcCtD
Celecoxib—Anaphylactic shock—Dexamethasone—psoriasis	2.97e-05	0.000218	CcSEcCtD
Celecoxib—Oedema—Betamethasone—psoriasis	2.97e-05	0.000218	CcSEcCtD
Celecoxib—Anaphylactic shock—Betamethasone—psoriasis	2.97e-05	0.000218	CcSEcCtD
Celecoxib—Oedema—Dexamethasone—psoriasis	2.97e-05	0.000218	CcSEcCtD
Celecoxib—Insomnia—Triamcinolone—psoriasis	2.96e-05	0.000218	CcSEcCtD
Celecoxib—Infection—Betamethasone—psoriasis	2.95e-05	0.000217	CcSEcCtD
Celecoxib—Infection—Dexamethasone—psoriasis	2.95e-05	0.000217	CcSEcCtD
Celecoxib—Paraesthesia—Triamcinolone—psoriasis	2.94e-05	0.000216	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisolone—psoriasis	2.93e-05	0.000216	CcSEcCtD
Celecoxib—Anaemia—Prednisone—psoriasis	2.93e-05	0.000215	CcSEcCtD
Celecoxib—Shock—Dexamethasone—psoriasis	2.92e-05	0.000215	CcSEcCtD
Celecoxib—Shock—Betamethasone—psoriasis	2.92e-05	0.000215	CcSEcCtD
Celecoxib—Dyspnoea—Triamcinolone—psoriasis	2.92e-05	0.000215	CcSEcCtD
Celecoxib—Nervous system disorder—Betamethasone—psoriasis	2.91e-05	0.000214	CcSEcCtD
Celecoxib—Nervous system disorder—Dexamethasone—psoriasis	2.91e-05	0.000214	CcSEcCtD
Celecoxib—Thrombocytopenia—Dexamethasone—psoriasis	2.91e-05	0.000214	CcSEcCtD
Celecoxib—Thrombocytopenia—Betamethasone—psoriasis	2.91e-05	0.000214	CcSEcCtD
Celecoxib—Tachycardia—Dexamethasone—psoriasis	2.9e-05	0.000213	CcSEcCtD
Celecoxib—Tachycardia—Betamethasone—psoriasis	2.9e-05	0.000213	CcSEcCtD
Celecoxib—Angioedema—Prednisone—psoriasis	2.9e-05	0.000213	CcSEcCtD
Celecoxib—Hypersensitivity—Cyclosporine—psoriasis	2.88e-05	0.000212	CcSEcCtD
Celecoxib—Dyspepsia—Triamcinolone—psoriasis	2.88e-05	0.000212	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—psoriasis	2.88e-05	0.000211	CcSEcCtD
Celecoxib—Nausea—Mycophenolic acid—psoriasis	2.87e-05	0.000211	CcSEcCtD
Celecoxib—Hyperhidrosis—Betamethasone—psoriasis	2.87e-05	0.000211	CcSEcCtD
Celecoxib—Hyperhidrosis—Dexamethasone—psoriasis	2.87e-05	0.000211	CcSEcCtD
Celecoxib—Feeling abnormal—Hydrocortisone—psoriasis	2.86e-05	0.000211	CcSEcCtD
Celecoxib—Vertigo—Prednisone—psoriasis	2.85e-05	0.000209	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—psoriasis	2.84e-05	0.000209	CcSEcCtD
Celecoxib—Gastrointestinal pain—Hydrocortisone—psoriasis	2.84e-05	0.000209	CcSEcCtD
Celecoxib—Syncope—Prednisone—psoriasis	2.84e-05	0.000209	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—psoriasis	2.84e-05	0.000209	CcSEcCtD
Celecoxib—Anorexia—Dexamethasone—psoriasis	2.83e-05	0.000208	CcSEcCtD
Celecoxib—Anorexia—Betamethasone—psoriasis	2.83e-05	0.000208	CcSEcCtD
Celecoxib—Urticaria—Prednisolone—psoriasis	2.83e-05	0.000208	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—psoriasis	2.82e-05	0.000208	CcSEcCtD
Celecoxib—Fatigue—Triamcinolone—psoriasis	2.82e-05	0.000207	CcSEcCtD
Celecoxib—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.81e-05	0.000207	CcSEcCtD
Celecoxib—Asthenia—Cyclosporine—psoriasis	2.81e-05	0.000206	CcSEcCtD
Celecoxib—Loss of consciousness—Prednisone—psoriasis	2.79e-05	0.000205	CcSEcCtD
Celecoxib—Pruritus—Cyclosporine—psoriasis	2.77e-05	0.000203	CcSEcCtD
Celecoxib—Urticaria—Hydrocortisone—psoriasis	2.76e-05	0.000203	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—psoriasis	2.76e-05	0.000203	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—psoriasis	2.75e-05	0.000202	CcSEcCtD
Celecoxib—Abdominal pain—Hydrocortisone—psoriasis	2.75e-05	0.000202	CcSEcCtD
Celecoxib—Body temperature increased—Hydrocortisone—psoriasis	2.75e-05	0.000202	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—psoriasis	2.74e-05	0.000202	CcSEcCtD
Celecoxib—Asthenia—Mycophenolate mofetil—psoriasis	2.74e-05	0.000201	CcSEcCtD
Celecoxib—Hypertension—Prednisone—psoriasis	2.74e-05	0.000201	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.71e-05	0.000199	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Betamethasone—psoriasis	2.71e-05	0.000199	CcSEcCtD
Celecoxib—Pruritus—Mycophenolate mofetil—psoriasis	2.7e-05	0.000198	CcSEcCtD
Celecoxib—Myalgia—Prednisone—psoriasis	2.7e-05	0.000198	CcSEcCtD
Celecoxib—Arthralgia—Prednisone—psoriasis	2.7e-05	0.000198	CcSEcCtD
Celecoxib—Feeling abnormal—Triamcinolone—psoriasis	2.7e-05	0.000198	CcSEcCtD
Celecoxib—Anxiety—Prednisone—psoriasis	2.69e-05	0.000198	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—psoriasis	2.69e-05	0.000198	CcSEcCtD
Celecoxib—Insomnia—Betamethasone—psoriasis	2.69e-05	0.000197	CcSEcCtD
Celecoxib—Insomnia—Dexamethasone—psoriasis	2.69e-05	0.000197	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.68e-05	0.000197	CcSEcCtD
Celecoxib—Diarrhoea—Cyclosporine—psoriasis	2.68e-05	0.000197	CcSEcCtD
Celecoxib—Paraesthesia—Dexamethasone—psoriasis	2.67e-05	0.000196	CcSEcCtD
Celecoxib—Paraesthesia—Betamethasone—psoriasis	2.67e-05	0.000196	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—psoriasis	2.67e-05	0.000196	CcSEcCtD
Celecoxib—Hypersensitivity—Prednisolone—psoriasis	2.62e-05	0.000193	CcSEcCtD
Celecoxib—Dyspepsia—Betamethasone—psoriasis	2.61e-05	0.000192	CcSEcCtD
Celecoxib—Dyspepsia—Dexamethasone—psoriasis	2.61e-05	0.000192	CcSEcCtD
Celecoxib—Diarrhoea—Mycophenolate mofetil—psoriasis	2.61e-05	0.000192	CcSEcCtD
Celecoxib—CA5B—Metabolism—CAT—psoriasis	2.6e-05	0.000463	CbGpPWpGaD
Celecoxib—Urticaria—Triamcinolone—psoriasis	2.6e-05	0.000191	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—psoriasis	2.59e-05	0.000191	CcSEcCtD
Celecoxib—Body temperature increased—Triamcinolone—psoriasis	2.59e-05	0.00019	CcSEcCtD
Celecoxib—Dizziness—Cyclosporine—psoriasis	2.59e-05	0.00019	CcSEcCtD
Celecoxib—Oedema—Prednisone—psoriasis	2.59e-05	0.00019	CcSEcCtD
Celecoxib—Anaphylactic shock—Prednisone—psoriasis	2.59e-05	0.00019	CcSEcCtD
Celecoxib—Decreased appetite—Dexamethasone—psoriasis	2.58e-05	0.00019	CcSEcCtD
Celecoxib—Decreased appetite—Betamethasone—psoriasis	2.58e-05	0.00019	CcSEcCtD
Celecoxib—MAPK14—MAPK Signaling Pathway—NFKB1—psoriasis	2.58e-05	0.000459	CbGpPWpGaD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	2.58e-05	0.000459	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—psoriasis	2.58e-05	0.000459	CbGpPWpGaD
Celecoxib—Infection—Prednisone—psoriasis	2.57e-05	0.000189	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Betamethasone—psoriasis	2.56e-05	0.000188	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Dexamethasone—psoriasis	2.56e-05	0.000188	CcSEcCtD
Celecoxib—Back pain—Methotrexate—psoriasis	2.56e-05	0.000188	CcSEcCtD
Celecoxib—Hypersensitivity—Hydrocortisone—psoriasis	2.56e-05	0.000188	CcSEcCtD
Celecoxib—Fatigue—Betamethasone—psoriasis	2.56e-05	0.000188	CcSEcCtD
Celecoxib—Fatigue—Dexamethasone—psoriasis	2.56e-05	0.000188	CcSEcCtD
Celecoxib—Shock—Prednisone—psoriasis	2.54e-05	0.000187	CcSEcCtD
Celecoxib—Nervous system disorder—Prednisone—psoriasis	2.54e-05	0.000186	CcSEcCtD
Celecoxib—CA9—Metabolism—CARM1—psoriasis	2.53e-05	0.000449	CbGpPWpGaD
Celecoxib—Tachycardia—Prednisone—psoriasis	2.52e-05	0.000186	CcSEcCtD
Celecoxib—Dizziness—Mycophenolate mofetil—psoriasis	2.52e-05	0.000185	CcSEcCtD
Celecoxib—Skin disorder—Prednisone—psoriasis	2.51e-05	0.000185	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—TAGAP—psoriasis	2.5e-05	0.000445	CbGpPWpGaD
Celecoxib—Hyperhidrosis—Prednisone—psoriasis	2.5e-05	0.000184	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—psoriasis	2.5e-05	0.000183	CcSEcCtD
Celecoxib—Asthenia—Hydrocortisone—psoriasis	2.49e-05	0.000183	CcSEcCtD
Celecoxib—Vomiting—Cyclosporine—psoriasis	2.49e-05	0.000183	CcSEcCtD
Celecoxib—MAPK14—MyD88-independent cascade—IL6—psoriasis	2.47e-05	0.00044	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—JUN—psoriasis	2.47e-05	0.00044	CbGpPWpGaD
Celecoxib—Rash—Cyclosporine—psoriasis	2.47e-05	0.000181	CcSEcCtD
Celecoxib—Anorexia—Prednisone—psoriasis	2.47e-05	0.000181	CcSEcCtD
Celecoxib—Dermatitis—Cyclosporine—psoriasis	2.46e-05	0.000181	CcSEcCtD
Celecoxib—Pruritus—Hydrocortisone—psoriasis	2.46e-05	0.000181	CcSEcCtD
Celecoxib—PDPK1—Immune System—SOCS1—psoriasis	2.46e-05	0.000437	CbGpPWpGaD
Celecoxib—Headache—Cyclosporine—psoriasis	2.45e-05	0.00018	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—psoriasis	2.45e-05	0.00018	CcSEcCtD
Celecoxib—Feeling abnormal—Dexamethasone—psoriasis	2.45e-05	0.00018	CcSEcCtD
Celecoxib—Feeling abnormal—Betamethasone—psoriasis	2.45e-05	0.00018	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	2.44e-05	0.000435	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Dexamethasone—psoriasis	2.43e-05	0.000179	CcSEcCtD
Celecoxib—Gastrointestinal pain—Betamethasone—psoriasis	2.43e-05	0.000179	CcSEcCtD
Celecoxib—Vomiting—Mycophenolate mofetil—psoriasis	2.43e-05	0.000178	CcSEcCtD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.42e-05	0.000431	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL6—psoriasis	2.41e-05	0.00043	CbGpPWpGaD
Celecoxib—Hypersensitivity—Triamcinolone—psoriasis	2.41e-05	0.000177	CcSEcCtD
Celecoxib—CA12—Metabolism—CAT—psoriasis	2.41e-05	0.000429	CbGpPWpGaD
Celecoxib—Rash—Mycophenolate mofetil—psoriasis	2.41e-05	0.000177	CcSEcCtD
Celecoxib—Dermatitis—Mycophenolate mofetil—psoriasis	2.4e-05	0.000177	CcSEcCtD
Celecoxib—Headache—Mycophenolate mofetil—psoriasis	2.39e-05	0.000176	CcSEcCtD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—STAT3—psoriasis	2.39e-05	0.000425	CbGpPWpGaD
Celecoxib—Vertigo—Methotrexate—psoriasis	2.38e-05	0.000175	CcSEcCtD
Celecoxib—Diarrhoea—Hydrocortisone—psoriasis	2.38e-05	0.000175	CcSEcCtD
Celecoxib—MAPK14—Cellular Senescence—NFKB1—psoriasis	2.38e-05	0.000423	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—TYK2—psoriasis	2.37e-05	0.000423	CbGpPWpGaD
Celecoxib—Leukopenia—Methotrexate—psoriasis	2.37e-05	0.000174	CcSEcCtD
Celecoxib—Urticaria—Dexamethasone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Celecoxib—Urticaria—Betamethasone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IL6—psoriasis	2.36e-05	0.00042	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Prednisone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Celecoxib—Dizziness—Prednisolone—psoriasis	2.35e-05	0.000173	CcSEcCtD
Celecoxib—Asthenia—Triamcinolone—psoriasis	2.35e-05	0.000173	CcSEcCtD
Celecoxib—Body temperature increased—Betamethasone—psoriasis	2.35e-05	0.000173	CcSEcCtD
Celecoxib—Abdominal pain—Betamethasone—psoriasis	2.35e-05	0.000173	CcSEcCtD
Celecoxib—Body temperature increased—Dexamethasone—psoriasis	2.35e-05	0.000173	CcSEcCtD
Celecoxib—Abdominal pain—Dexamethasone—psoriasis	2.35e-05	0.000173	CcSEcCtD
Celecoxib—PTGS2—Metabolism—NDUFA5—psoriasis	2.34e-05	0.000417	CbGpPWpGaD
Celecoxib—Insomnia—Prednisone—psoriasis	2.34e-05	0.000172	CcSEcCtD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	2.34e-05	0.000416	CbGpPWpGaD
Celecoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—psoriasis	2.33e-05	0.000415	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.33e-05	0.000415	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.33e-05	0.000414	CbGpPWpGaD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—IL6—psoriasis	2.32e-05	0.000414	CbGpPWpGaD
Celecoxib—Nausea—Cyclosporine—psoriasis	2.32e-05	0.000171	CcSEcCtD
Celecoxib—Paraesthesia—Prednisone—psoriasis	2.32e-05	0.000171	CcSEcCtD
Celecoxib—Pruritus—Triamcinolone—psoriasis	2.32e-05	0.00017	CcSEcCtD
Celecoxib—Cough—Methotrexate—psoriasis	2.31e-05	0.00017	CcSEcCtD
Celecoxib—Dizziness—Hydrocortisone—psoriasis	2.3e-05	0.000169	CcSEcCtD
Celecoxib—Dyspepsia—Prednisone—psoriasis	2.28e-05	0.000167	CcSEcCtD
Celecoxib—Nausea—Mycophenolate mofetil—psoriasis	2.27e-05	0.000167	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—psoriasis	2.25e-05	0.000166	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—psoriasis	2.25e-05	0.000166	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—psoriasis	2.25e-05	0.000166	CcSEcCtD
Celecoxib—Decreased appetite—Prednisone—psoriasis	2.25e-05	0.000165	CcSEcCtD
Celecoxib—Rash—Prednisolone—psoriasis	2.24e-05	0.000165	CcSEcCtD
Celecoxib—Dermatitis—Prednisolone—psoriasis	2.24e-05	0.000165	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.24e-05	0.000165	CcSEcCtD
Celecoxib—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.24e-05	0.000398	CbGpPWpGaD
Celecoxib—Fatigue—Prednisone—psoriasis	2.23e-05	0.000164	CcSEcCtD
Celecoxib—Headache—Prednisolone—psoriasis	2.23e-05	0.000164	CcSEcCtD
Celecoxib—MAPK14—Activated TLR4 signalling—IL6—psoriasis	2.22e-05	0.000396	CbGpPWpGaD
Celecoxib—CA14—Metabolism—APOE—psoriasis	2.22e-05	0.000396	CbGpPWpGaD
Celecoxib—Constipation—Prednisone—psoriasis	2.21e-05	0.000163	CcSEcCtD
Celecoxib—Vomiting—Hydrocortisone—psoriasis	2.21e-05	0.000162	CcSEcCtD
Celecoxib—MAPK14—Signaling by VEGF—IL6—psoriasis	2.19e-05	0.00039	CbGpPWpGaD
Celecoxib—Rash—Hydrocortisone—psoriasis	2.19e-05	0.000161	CcSEcCtD
Celecoxib—ALB—Platelet degranulation—VEGFA—psoriasis	2.19e-05	0.00039	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—SOCS1—psoriasis	2.19e-05	0.00039	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TNF—psoriasis	2.19e-05	0.00039	CbGpPWpGaD
Celecoxib—Dermatitis—Hydrocortisone—psoriasis	2.19e-05	0.000161	CcSEcCtD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.19e-05	0.000389	CbGpPWpGaD
Celecoxib—Confusional state—Methotrexate—psoriasis	2.18e-05	0.00016	CcSEcCtD
Celecoxib—Headache—Hydrocortisone—psoriasis	2.18e-05	0.00016	CcSEcCtD
Celecoxib—PDPK1—Immune System—CD8A—psoriasis	2.18e-05	0.000388	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.17e-05	0.000387	CbGpPWpGaD
Celecoxib—CA6—Metabolism—APOE—psoriasis	2.17e-05	0.000385	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—APOE—psoriasis	2.17e-05	0.000385	CbGpPWpGaD
Celecoxib—Dizziness—Triamcinolone—psoriasis	2.16e-05	0.000159	CcSEcCtD
Celecoxib—MAPK14—Signaling by NGF—TYK2—psoriasis	2.16e-05	0.000385	CbGpPWpGaD
Celecoxib—Anaphylactic shock—Methotrexate—psoriasis	2.16e-05	0.000159	CcSEcCtD
Celecoxib—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.15e-05	0.000383	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.15e-05	0.000382	CbGpPWpGaD
Celecoxib—Infection—Methotrexate—psoriasis	2.15e-05	0.000158	CcSEcCtD
Celecoxib—PDPK1—Innate Immune System—CD4—psoriasis	2.15e-05	0.000382	CbGpPWpGaD
Celecoxib—MAPK14—TGF-beta Signaling Pathway—TP53—psoriasis	2.15e-05	0.000382	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ITGAL—psoriasis	2.14e-05	0.000381	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—STAT3—psoriasis	2.14e-05	0.00038	CbGpPWpGaD
Celecoxib—Feeling abnormal—Prednisone—psoriasis	2.13e-05	0.000157	CcSEcCtD
Celecoxib—Asthenia—Betamethasone—psoriasis	2.13e-05	0.000157	CcSEcCtD
Celecoxib—Asthenia—Dexamethasone—psoriasis	2.13e-05	0.000157	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—psoriasis	2.12e-05	0.000156	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—psoriasis	2.12e-05	0.000156	CcSEcCtD
Celecoxib—Gastrointestinal pain—Prednisone—psoriasis	2.12e-05	0.000155	CcSEcCtD
Celecoxib—Nausea—Prednisolone—psoriasis	2.11e-05	0.000155	CcSEcCtD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.11e-05	0.000376	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—ITGAL—psoriasis	2.11e-05	0.000375	CbGpPWpGaD
Celecoxib—Pruritus—Betamethasone—psoriasis	2.1e-05	0.000154	CcSEcCtD
Celecoxib—Pruritus—Dexamethasone—psoriasis	2.1e-05	0.000154	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—psoriasis	2.1e-05	0.000154	CcSEcCtD
Celecoxib—PDPK1—Immune System—HLA-B—psoriasis	2.09e-05	0.000373	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	2.09e-05	0.000372	CbGpPWpGaD
Celecoxib—Hyperhidrosis—Methotrexate—psoriasis	2.09e-05	0.000154	CcSEcCtD
Celecoxib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.09e-05	0.000372	CbGpPWpGaD
Celecoxib—Vomiting—Triamcinolone—psoriasis	2.08e-05	0.000153	CcSEcCtD
Celecoxib—Nausea—Hydrocortisone—psoriasis	2.06e-05	0.000152	CcSEcCtD
Celecoxib—Rash—Triamcinolone—psoriasis	2.06e-05	0.000152	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—CD4—psoriasis	2.06e-05	0.000367	CbGpPWpGaD
Celecoxib—Dermatitis—Triamcinolone—psoriasis	2.06e-05	0.000152	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—psoriasis	2.06e-05	0.000151	CcSEcCtD
Celecoxib—Urticaria—Prednisone—psoriasis	2.05e-05	0.000151	CcSEcCtD
Celecoxib—Headache—Triamcinolone—psoriasis	2.05e-05	0.000151	CcSEcCtD
Celecoxib—Body temperature increased—Prednisone—psoriasis	2.04e-05	0.00015	CcSEcCtD
Celecoxib—Abdominal pain—Prednisone—psoriasis	2.04e-05	0.00015	CcSEcCtD
Celecoxib—CA9—Cellular responses to stress—TP53—psoriasis	2.04e-05	0.000364	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—IL6—psoriasis	2.04e-05	0.000362	CbGpPWpGaD
Celecoxib—Diarrhoea—Betamethasone—psoriasis	2.03e-05	0.000149	CcSEcCtD
Celecoxib—Diarrhoea—Dexamethasone—psoriasis	2.03e-05	0.000149	CcSEcCtD
Celecoxib—CA5B—Metabolism—APOE—psoriasis	2.02e-05	0.00036	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—CXCL8—psoriasis	2.01e-05	0.000357	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TNF—psoriasis	2.01e-05	0.000357	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—REL—psoriasis	2e-05	0.000356	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP2S1—psoriasis	1.99e-05	0.000355	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	1.97e-05	0.000351	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Methotrexate—psoriasis	1.97e-05	0.000145	CcSEcCtD
Celecoxib—Dizziness—Betamethasone—psoriasis	1.96e-05	0.000144	CcSEcCtD
Celecoxib—Dizziness—Dexamethasone—psoriasis	1.96e-05	0.000144	CcSEcCtD
Celecoxib—MAPK14—Gene Expression—CARM1—psoriasis	1.96e-05	0.000349	CbGpPWpGaD
Celecoxib—Insomnia—Methotrexate—psoriasis	1.96e-05	0.000144	CcSEcCtD
Celecoxib—Nausea—Triamcinolone—psoriasis	1.94e-05	0.000143	CcSEcCtD
Celecoxib—MAPK14—Immune System—IFIH1—psoriasis	1.94e-05	0.000346	CbGpPWpGaD
Celecoxib—Paraesthesia—Methotrexate—psoriasis	1.94e-05	0.000143	CcSEcCtD
Celecoxib—PDPK1—Immune System—HLA-A—psoriasis	1.94e-05	0.000346	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PPARG—psoriasis	1.94e-05	0.000345	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TP53—psoriasis	1.93e-05	0.000344	CbGpPWpGaD
Celecoxib—Dyspnoea—Methotrexate—psoriasis	1.93e-05	0.000142	CcSEcCtD
Celecoxib—PDPK1—Innate Immune System—JUN—psoriasis	1.92e-05	0.000342	CbGpPWpGaD
Celecoxib—CA4—Metabolism—CAT—psoriasis	1.92e-05	0.000342	CbGpPWpGaD
Celecoxib—Somnolence—Methotrexate—psoriasis	1.92e-05	0.000141	CcSEcCtD
Celecoxib—ABCC4—Hemostasis—NOS2—psoriasis	1.91e-05	0.00034	CbGpPWpGaD
Celecoxib—Hypersensitivity—Prednisone—psoriasis	1.91e-05	0.00014	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—psoriasis	1.9e-05	0.00014	CcSEcCtD
Celecoxib—ALB—Metabolism—NDUFA5—psoriasis	1.9e-05	0.000338	CbGpPWpGaD
Celecoxib—Vomiting—Dexamethasone—psoriasis	1.89e-05	0.000139	CcSEcCtD
Celecoxib—Vomiting—Betamethasone—psoriasis	1.89e-05	0.000139	CcSEcCtD
Celecoxib—CA5A—Metabolism—PPARG—psoriasis	1.89e-05	0.000336	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PPARG—psoriasis	1.89e-05	0.000336	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	1.88e-05	0.000335	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.88e-05	0.000335	CbGpPWpGaD
Celecoxib—Decreased appetite—Methotrexate—psoriasis	1.88e-05	0.000138	CcSEcCtD
Celecoxib—CA12—Metabolism—APOE—psoriasis	1.87e-05	0.000333	CbGpPWpGaD
Celecoxib—Rash—Betamethasone—psoriasis	1.87e-05	0.000138	CcSEcCtD
Celecoxib—Rash—Dexamethasone—psoriasis	1.87e-05	0.000138	CcSEcCtD
Celecoxib—Dermatitis—Dexamethasone—psoriasis	1.87e-05	0.000138	CcSEcCtD
Celecoxib—Dermatitis—Betamethasone—psoriasis	1.87e-05	0.000138	CcSEcCtD
Celecoxib—CA9—Cellular responses to stress—IL6—psoriasis	1.87e-05	0.000333	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HLA-B—psoriasis	1.87e-05	0.000333	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—JUN—psoriasis	1.87e-05	0.000332	CbGpPWpGaD
Celecoxib—Gastrointestinal disorder—Methotrexate—psoriasis	1.87e-05	0.000137	CcSEcCtD
Celecoxib—PDPK1—Hemostasis—VEGFA—psoriasis	1.87e-05	0.000332	CbGpPWpGaD
Celecoxib—Fatigue—Methotrexate—psoriasis	1.86e-05	0.000137	CcSEcCtD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—IL6—psoriasis	1.86e-05	0.000332	CbGpPWpGaD
Celecoxib—Headache—Dexamethasone—psoriasis	1.86e-05	0.000137	CcSEcCtD
Celecoxib—Headache—Betamethasone—psoriasis	1.86e-05	0.000137	CcSEcCtD
Celecoxib—Asthenia—Prednisone—psoriasis	1.86e-05	0.000136	CcSEcCtD
Celecoxib—PDPK1—Immune System—CRP—psoriasis	1.85e-05	0.00033	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—NFKB1—psoriasis	1.85e-05	0.000329	CbGpPWpGaD
Celecoxib—CA2—Metabolism—CAT—psoriasis	1.84e-05	0.000328	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-C—psoriasis	1.84e-05	0.000328	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—LEP—psoriasis	1.83e-05	0.000326	CbGpPWpGaD
Celecoxib—Pruritus—Prednisone—psoriasis	1.83e-05	0.000135	CcSEcCtD
Celecoxib—MAPK14—Immune System—TNFAIP3—psoriasis	1.82e-05	0.000324	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.81e-05	0.000322	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—NFKB1—psoriasis	1.8e-05	0.00032	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HLA-A—psoriasis	1.79e-05	0.000319	CbGpPWpGaD
Celecoxib—Feeling abnormal—Methotrexate—psoriasis	1.78e-05	0.000131	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—NFKB1—psoriasis	1.78e-05	0.000316	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-DRB1—psoriasis	1.77e-05	0.000316	CbGpPWpGaD
Celecoxib—Diarrhoea—Prednisone—psoriasis	1.77e-05	0.00013	CcSEcCtD
Celecoxib—MAPK14—MAPK Signaling Pathway—TP53—psoriasis	1.77e-05	0.000315	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.77e-05	0.000315	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Methotrexate—psoriasis	1.77e-05	0.00013	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—IL6—psoriasis	1.77e-05	0.000315	CbGpPWpGaD
Celecoxib—Nausea—Dexamethasone—psoriasis	1.76e-05	0.00013	CcSEcCtD
Celecoxib—Nausea—Betamethasone—psoriasis	1.76e-05	0.00013	CcSEcCtD
Celecoxib—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.76e-05	0.000314	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PPARG—psoriasis	1.76e-05	0.000313	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.74e-05	0.00031	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	1.74e-05	0.000309	CbGpPWpGaD
Celecoxib—Urticaria—Methotrexate—psoriasis	1.72e-05	0.000126	CcSEcCtD
Celecoxib—Dizziness—Prednisone—psoriasis	1.71e-05	0.000126	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—psoriasis	1.71e-05	0.000126	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—psoriasis	1.71e-05	0.000126	CcSEcCtD
Celecoxib—PDPK1—Immune System—ICAM1—psoriasis	1.7e-05	0.000303	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TNF—psoriasis	1.7e-05	0.000303	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NFKBIA—psoriasis	1.69e-05	0.000301	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—NFKB1—psoriasis	1.69e-05	0.0003	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.68e-05	0.000299	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—NOS2—psoriasis	1.67e-05	0.000298	CbGpPWpGaD
Celecoxib—PDPK1—Disease—APOE—psoriasis	1.67e-05	0.000298	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CRP—psoriasis	1.65e-05	0.000294	CbGpPWpGaD
Celecoxib—Vomiting—Prednisone—psoriasis	1.64e-05	0.000121	CcSEcCtD
Celecoxib—CA12—Metabolism—PPARG—psoriasis	1.63e-05	0.00029	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—VEGFA—psoriasis	1.63e-05	0.00029	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—TP53—psoriasis	1.63e-05	0.00029	CbGpPWpGaD
Celecoxib—Rash—Prednisone—psoriasis	1.63e-05	0.00012	CcSEcCtD
Celecoxib—Dermatitis—Prednisone—psoriasis	1.63e-05	0.00012	CcSEcCtD
Celecoxib—Headache—Prednisone—psoriasis	1.62e-05	0.000119	CcSEcCtD
Celecoxib—MAPK14—Cellular responses to stress—STAT3—psoriasis	1.62e-05	0.000287	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000287	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.6e-05	0.000284	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—PPARG—psoriasis	1.59e-05	0.000284	CbGpPWpGaD
Celecoxib—Hypersensitivity—Methotrexate—psoriasis	1.59e-05	0.000117	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—SOCS1—psoriasis	1.59e-05	0.000283	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NDUFA5—psoriasis	1.57e-05	0.000279	CbGpPWpGaD
Celecoxib—PDPK1—Disease—NOS2—psoriasis	1.56e-05	0.000278	CbGpPWpGaD
Celecoxib—CA9—Metabolism—CAT—psoriasis	1.55e-05	0.000276	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NDUFA5—psoriasis	1.55e-05	0.000276	CbGpPWpGaD
Celecoxib—Asthenia—Methotrexate—psoriasis	1.55e-05	0.000114	CcSEcCtD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.55e-05	0.000275	CbGpPWpGaD
Celecoxib—Nausea—Prednisone—psoriasis	1.54e-05	0.000113	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—psoriasis	1.53e-05	0.000112	CcSEcCtD
Celecoxib—MAPK14—Immune System—HLA-E—psoriasis	1.53e-05	0.000272	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—STAT3—psoriasis	1.51e-05	0.00027	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—TYK2—psoriasis	1.51e-05	0.000269	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NFKBIA—psoriasis	1.51e-05	0.000268	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.5e-05	0.000267	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL20—psoriasis	1.5e-05	0.000267	CbGpPWpGaD
Celecoxib—CA4—Metabolism—APOE—psoriasis	1.49e-05	0.000266	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—IL6—psoriasis	1.49e-05	0.000266	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.49e-05	0.000265	CbGpPWpGaD
Celecoxib—Diarrhoea—Methotrexate—psoriasis	1.48e-05	0.000109	CcSEcCtD
Celecoxib—PDPK1—GPCR downstream signaling—CXCL8—psoriasis	1.45e-05	0.000258	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.45e-05	0.000258	CbGpPWpGaD
Celecoxib—CA2—Metabolism—APOE—psoriasis	1.43e-05	0.000255	CbGpPWpGaD
Celecoxib—Dizziness—Methotrexate—psoriasis	1.43e-05	0.000105	CcSEcCtD
Celecoxib—PDPK1—Hemostasis—TP53—psoriasis	1.41e-05	0.000251	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.4e-05	0.00025	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TYK2—psoriasis	1.4e-05	0.000249	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—TYK2—psoriasis	1.38e-05	0.000246	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.38e-05	0.000245	CbGpPWpGaD
Celecoxib—Vomiting—Methotrexate—psoriasis	1.37e-05	0.000101	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.37e-05	0.000244	CbGpPWpGaD
Celecoxib—Rash—Methotrexate—psoriasis	1.36e-05	0.0001	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—psoriasis	1.36e-05	0.0001	CcSEcCtD
Celecoxib—Headache—Methotrexate—psoriasis	1.35e-05	9.95e-05	CcSEcCtD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.35e-05	0.00024	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP2S1—psoriasis	1.33e-05	0.000237	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP2S1—psoriasis	1.32e-05	0.000235	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CXCL8—psoriasis	1.32e-05	0.000235	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PPARG—psoriasis	1.3e-05	0.000232	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IFNG—psoriasis	1.3e-05	0.000231	CbGpPWpGaD
Celecoxib—Nausea—Methotrexate—psoriasis	1.28e-05	9.44e-05	CcSEcCtD
Celecoxib—PDPK1—Disease—TYK2—psoriasis	1.28e-05	0.000227	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—SOCS1—psoriasis	1.28e-05	0.000227	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD4—psoriasis	1.25e-05	0.000223	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PPARG—psoriasis	1.25e-05	0.000222	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—TYK2—psoriasis	1.23e-05	0.00022	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—TP53—psoriasis	1.23e-05	0.000219	CbGpPWpGaD
Celecoxib—CA9—Metabolism—APOE—psoriasis	1.21e-05	0.000215	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—LEP—psoriasis	1.17e-05	0.000209	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—APOE—psoriasis	1.17e-05	0.000209	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—VDR—psoriasis	1.17e-05	0.000208	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—IL6—psoriasis	1.16e-05	0.000207	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.16e-05	0.000206	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CD4—psoriasis	1.15e-05	0.000206	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD8A—psoriasis	1.13e-05	0.000201	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—IL6—psoriasis	1.13e-05	0.000201	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—JUN—psoriasis	1.12e-05	0.000199	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CD4—psoriasis	1.12e-05	0.000199	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—VEGFA—psoriasis	1.11e-05	0.000197	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NFKBIA—psoriasis	1.09e-05	0.000194	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—NFKB1—psoriasis	1.09e-05	0.000194	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-B—psoriasis	1.09e-05	0.000194	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NFKB1—psoriasis	1.08e-05	0.000192	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—IL6—psoriasis	1.06e-05	0.000188	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PPARG—psoriasis	1.05e-05	0.000187	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.04e-05	0.000186	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NDUFA5—psoriasis	1.02e-05	0.000182	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.02e-05	0.000182	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-A—psoriasis	1.01e-05	0.00018	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—JUN—psoriasis	9.99e-06	0.000178	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—VEGFA—psoriasis	9.88e-06	0.000176	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—STAT3—psoriasis	9.78e-06	0.000174	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CARM1—psoriasis	9.73e-06	0.000173	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	9.72e-06	0.000173	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—VEGFA—psoriasis	9.69e-06	0.000173	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—STAT3—psoriasis	9.68e-06	0.000172	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CRP—psoriasis	9.62e-06	0.000171	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NFKB1—psoriasis	9.61e-06	0.000171	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DRB1—psoriasis	9.22e-06	0.000164	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.1e-06	0.000162	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TYK2—psoriasis	8.94e-06	0.000159	CbGpPWpGaD
Celecoxib—PDPK1—Disease—STAT3—psoriasis	8.94e-06	0.000159	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ICAM1—psoriasis	8.84e-06	0.000157	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NFKBIA—psoriasis	8.77e-06	0.000156	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP2S1—psoriasis	8.7e-06	0.000155	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NOS2—psoriasis	8.65e-06	0.000154	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—psoriasis	8.47e-06	0.000151	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.45e-06	0.00015	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—psoriasis	8.37e-06	0.000149	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SOCS1—psoriasis	8.25e-06	0.000147	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—PPARG—psoriasis	8.16e-06	0.000145	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CARM1—psoriasis	7.87e-06	0.00014	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCL8—psoriasis	7.79e-06	0.000139	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL6—psoriasis	7.4e-06	0.000132	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.36e-06	0.000131	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—psoriasis	7.32e-06	0.00013	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—JUN—psoriasis	7.24e-06	0.000129	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TYK2—psoriasis	7.19e-06	0.000128	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NFKB1—psoriasis	6.97e-06	0.000124	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.92e-06	0.000123	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—IL6—psoriasis	6.83e-06	0.000122	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL6—psoriasis	6.76e-06	0.00012	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNG—psoriasis	6.73e-06	0.00012	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CARM1—psoriasis	6.5e-06	0.000116	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD4—psoriasis	6.5e-06	0.000116	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CARM1—psoriasis	6.45e-06	0.000115	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—psoriasis	6.32e-06	0.000113	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—STAT3—psoriasis	6.26e-06	0.000111	CbGpPWpGaD
Celecoxib—PDPK1—Disease—IL6—psoriasis	6.25e-06	0.000111	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APOE—psoriasis	6.09e-06	0.000108	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—LEP—psoriasis	6.09e-06	0.000108	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IL6—psoriasis	6.04e-06	0.000107	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.02e-06	0.000107	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CAT—psoriasis	5.99e-06	0.000107	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HLA-A—psoriasis	5.95e-06	0.000106	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—JUN—psoriasis	5.82e-06	0.000104	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NFKBIA—psoriasis	5.67e-06	0.000101	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NFKB1—psoriasis	5.6e-06	9.97e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APOE—psoriasis	5.55e-06	9.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOS2—psoriasis	5.18e-06	9.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—psoriasis	5.03e-06	8.96e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—psoriasis	5.01e-06	8.92e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CAT—psoriasis	4.84e-06	8.62e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—psoriasis	4.78e-06	8.51e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—APOE—psoriasis	4.65e-06	8.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TYK2—psoriasis	4.65e-06	8.27e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—psoriasis	4.37e-06	7.79e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CARM1—psoriasis	4.25e-06	7.57e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TYK2—psoriasis	4.24e-06	7.55e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—psoriasis	4.05e-06	7.21e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL8—psoriasis	4.05e-06	7.2e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CAT—psoriasis	4e-06	7.12e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CAT—psoriasis	3.96e-06	7.06e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—psoriasis	3.83e-06	6.82e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—psoriasis	3.79e-06	6.74e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—APOE—psoriasis	3.76e-06	6.7e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—JUN—psoriasis	3.76e-06	6.7e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NFKB1—psoriasis	3.62e-06	6.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—psoriasis	3.52e-06	6.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—psoriasis	3.29e-06	5.85e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—psoriasis	3.28e-06	5.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—psoriasis	3.25e-06	5.79e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—APOE—psoriasis	3.11e-06	5.53e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—APOE—psoriasis	3.08e-06	5.48e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—psoriasis	2.97e-06	5.28e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—psoriasis	2.71e-06	4.82e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—psoriasis	2.68e-06	4.78e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CAT—psoriasis	2.61e-06	4.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—psoriasis	2.48e-06	4.42e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—psoriasis	2.27e-06	4.05e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—psoriasis	2.07e-06	3.69e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—APOE—psoriasis	2.03e-06	3.62e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—psoriasis	1.77e-06	3.15e-05	CbGpPWpGaD
